STOCKS TELEGRAPH

Tag: Novavax Inc

  • Investor Optimism As Novavax (NVAX) Reports Growth And Teams Up With Sanofi

    Investor Optimism As Novavax (NVAX) Reports Growth And Teams Up With Sanofi

    Novavax, Inc. (NASDAQ: NVAX) has experienced a significant surge in its stock performance, buoyed by the unveiling of its financial outcomes. In the latest market session, NVAX shares displayed an impressive escalation of 137.14%, attaining $10.60 as per the most recent evaluation. Furthermore, a notable strategic collaboration is also driving this ascent on the US stock indices.

    Financial Performance Highlights

    For the first quarter of 2024, Novavax (NVAX) disclosed a total revenue generation of $94 million, contrasting with $81 million from the preceding year. Meanwhile, the net loss of $148 million also exhibited an enhancement compared to the $294 million recorded in the prior year.

    Strategic Partnership With Sanofi

    Earlier today, Novavax also publicized its participation in a co-exclusive licensing pact with Sanofi. The synergistic alliance between Novavax and Sanofi will enhance their ability to advance their mission of developing and enhancing accessibility to life-saving vaccines. Novavax is also gearing up for the initiation of its Phase 3 CIC and standalone influenza initiative in the latter part of this year.

    This pact further validates Novavax’s technological framework and presents a substantial opportunity to foster value creation and bolster global public health. It fortifies Novavax’s financial standing and cash inflow, enabling a heightened focus on research and development as well as pipeline expansion to expedite growth and foster enduring value for stakeholders.

    Revenue Opportunities And Financial Implications

    This collaboration signifies a potential multi-billion dollar revenue prospect for Novavax. The cumulative value encompassing upfront payments in the near term, Sanofi’s equity infusion, and potential milestones linked with Nuvaxovid sales and Sanofi’s flu-COVID-19 amalgam vaccine development, stands at approximately $1.3 billion. Within ten days, Novavax will get a $500 million upfront payment.

    A nearly $70 million equity investment in Novavax common stock will also be given to the company today, securing a 4.9% minority share. Up to $350 million in milestones pertaining to Nuvaxovid activities are attainable by Novavax. In addition, Novavax stands to gain an extra $350 million in milestones related to Sanofi’s combined flu-COVID-19 vaccine.

  • Novavax, Inc. (NVAX) stock Continues to Gain Premarket. Here’s why?

    Novavax, Inc. (NVAX) stock Continues to Gain Premarket. Here’s why?

    Novavax, Inc. (NVAX) gained a further 9.56% at $238.10 premarket, at the last check on Monday. The stock has been gaining on the news of its Covid-19 vaccine getting Emergency Use Listing from WHO.

    In the previous market session, the stock gained 11.49% at its closing price of $217.32 with 11.12M shares exchanging. NVAX has continued gaining on the news and had increased by $25.00 at the time of writing.

    Currently, the 75.61 million outstanding shares of the company trade at a market capitalization of $16.43 billion.

    Emergency Use Listing for NVX-CoV2373

    On November 17, NVAX and Serum Institute of India Pvt. Ltd. (SII) announced NVAX-CoV2373 has been granted Emergency Use Listing by the WHO. Moreover, the NVAX-CoV2373 is a Covid-19 vaccine for 18 years and older individuals. Furthermore, the EUL was granted to the vaccine manufactured and marketed as COVOVAXTM by SII. COVOVAX is marketed in India along with its licensed areas. In addition, another EUL filing is being reviewed by WHO for the marketing of the vaccine as NuvaxovidTM by Novavax.

    Furthermore, WHO granted the EUL to the vaccine, based on the preclinical, manufacturing, and clinical trial data. Hence, the quality, safety, and efficacy of the vaccine proved to be of the required standards to qualify and attain the EUL.

    According to President and CEO of Novavax, Stanley C. Erck, the EUL authorization is a crucial step for worldwide access to a protein-based Covid-19 vaccine. Previously, COVOVAX was issued EUA in Indonesia and the Philippines. Currently, it is under review by various regulatory authorities throughout the world.

    NVAX’s PREVENT-19 Trial

    On December 15, NVAX published the results of its Phase 3 clinical trial of NVX-CoV2373 in the New England Journal of Medicine. Furthermore, the paper was published under the title ‘Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico’.

    According to the results, the NVX-CoV2373 showed:

    • 100% protection against moderate and severe disease
    • 2% efficacy in case of variants of concern
    • 4% efficacy against Covid-19 of any severity
    • mild-to-moderate and transient solicited adverse events
    • no safety concerns

    NVAX’s Financial Highlights

    On November 04, the company reported its financial results for the third quarter of 2021. Accordingly, NVAX had a net loss of $4.31 per share on revenue of $178.8 million in the third quarter of 2021. This compares to a net loss of $3.21 on revenue of $157.0 million in the year-ago quarter.

  • Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

    Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

    Moderna Inc (MRNA) was up 20.24%on Monday at $152.74. The biotechnology company has therefore applied for marketing authorizations for its coronavirus vaccine in the United States and Europe, which has been shown to be more than 94% successful in advanced clinical trials.

    Pfizer Inc (PFE) gained 2.90 percent to $38.31 and BioNTech SE (BNTX) added 12.96 percent to close at $124.24 on Monday. The drug manufacturing companies were able to receive regulatory approvals in the United Kingdom and the United States for their 95 percent successful vaccine candidate within a few days.

    Novavax Inc (NVAX) saw a rise of 10.99 percent to conclude the trading at $139.50. Stock of soared, while the biotechnology company again postponed the launch in the United States of a Phase III clinical trial of its Covid experimental vaccine, but cited a possible start-up in the coming weeks.

    S&P Global Inc (SPGI) was up 2.99 percent to $351.78. As expected, it announced IHS Markit’s acquisition of $44 billion in shares, the biggest merger and value acquisition since the beginning of the year. The total capitalization of IHS Markit is $37 billion.

    Airbnb is looking for a $30 billion to $33 billion valuation for its Wall Street IPO. Food distribution player, DoorDash, with its more than tripled sales in nine months and first quarterly profit, is also greedy for its IPO with a cap from $25 billion to $28 billion. Both companies are planning to join the Wall Street in mid-December.

    Netflix Inc (NFLX) slipped -0.13 percent to $490.70 in the last session. The video streaming service is expected to begin disclosing revenue of more than GBP 1 billion from British subscribers to tax authorities in the UK, according to the Guardian. The Guardian claims that Netflix’s decision could place pressure on other U.S. tech giants such as Google or Amazon, who are currently preventing such reporting by optimizing their taxation.